Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis

Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway

(2020) Laurent Dercle et al.   JNCI-Journal of the National Cancer Institute

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

(2020) Flora Mulkey et al.   Journal for ImmunoTherapy of Cancer

Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics

(2020) Laurent Dercle et al.   CLINICAL CANCER RESEARCH

Embracing imperfect datasets: A review of deep learning solutions for medical image segmentation

(2020) Nima Tajbakhsh et al.   MEDICAL IMAGE ANALYSIS

Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab

(2019) Carole Durot et al.   EUROPEAN RADIOLOGY

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

(2019) S Trebeschi et al.   ANNALS OF ONCOLOGY

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

(2018) Julia A Beaver et al.   LANCET ONCOLOGY

Radiomics of CT Features May Be Nonreproducible and Redundant: Influence of CT Acquisition Parameters

(2018) Roberto Berenguer et al.   RADIOLOGY

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

(2018) Roger Sun et al.   LANCET ONCOLOGY

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Assessing Agreement between Radiomic Features Computed for Multiple CT Imaging Settings

(2017) Lin Lu et al.   PLoS One

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence

(2017) Laurent Dercle et al.   Scientific Reports

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Reproducibility of radiomics for deciphering tumor phenotype with imaging

(2016) Binsheng Zhao et al.   Scientific Reports

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

Immortal Time Bias in Pharmacoepidemiology

(2007) S. Suissa   AMERICAN JOURNAL OF EPIDEMIOLOGY